What Is The Current and Historic Market Size Analysis Of The Lipid Regulators Market?
The lipid regulators market has seen considerable growth due to a variety of factors.
• The lipid regulators market has experienced strong growth in recent years. It will rise from $7.29 billion in 2024 to $7.82 billion in 2025, growing at a CAGR of 7.2%.
This growth is attributed to the prevalence of lifestyle diseases, the aging population, heightened awareness of lipid regulators, rising healthcare expenditure, and a focus on healthcare prevention.
What Is The Forecast For The Lipid Regulators Market Size?
The lipid regulators market is expected to maintain its strong growth trajectory in upcoming years.
• The lipid regulators market is projected to grow to $10.2 billion by 2029, with a CAGR of 6.9%.
Growth is driven by the rising prevalence of cardiovascular diseases, increasing obesity rates, and the demand for personalized medicine. Trends include drug development advancements, digital health solutions, value-based pricing, and over-the-counter medication demand.
What Are The Essential Drivers Behind The Growth Of The Lipid Regulators Market?
The increasing prevalence of cardiovascular diseases is expected to boost the angina pectoris drug market. Cardiovascular diseases, which affect the heart and blood vessels, are increasing due to aging populations, unhealthy lifestyles, and obesity. High cholesterol can lead to atherosclerosis, which is treated with lipid regulators to reduce the risk of heart attacks and strokes. The British Heart Foundation reported that 7.6 million people in the UK suffer from heart and circulatory diseases, responsible for about 27% of all deaths in the UK. As such, the rise in cardiovascular diseases is propelling the growth of the angina pectoris drug market.
How Is The Global Lipid Regulators Market Divided Into Key Segments?
The lipid regulators market covered in this report is segmented –
1) By Type: Lipid Regulators, Narcotic Analgesics, Angiotensin Converting Enzyme (ACE) Inhibitors, Respiratory Agents, Diuretics, Calcium Antagonists, Hormonal Contraceptives, Other Types
2) By Indication: Hypercholesterolemia, Hypertriglyceridemia, Coronary Artery Disease, Other Indications
3) By Administration: Oral, Injectable
4) By Application: Pharmaceuticals, Vaccines And Drugs, Scientific Research, Nutrition And Supplements, Food And Beverages, Other Applications
Subsegments:
1) By Lipid Regulators: Statins, Fibrates, Niacin, Omega-3 Fatty Acids
2) By Narcotic Analgesics: Opioid Analgesics, Combination Analgesics (Opioid And Non-opioid), Antagonists For Pain Relief
3) By Angiotensin Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril
4) By Respiratory Agents: Bronchodilators, Corticosteroids, Antihistamines
5) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics
6) By Calcium Antagonists: Dihydropyridines, Non-Dihydropyridines
7) By Hormonal Contraceptives: Oral Contraceptives, Injectable Contraceptives, Implantable Contraceptives
8) By Other Types: Beta Blockers, Anticoagulants, Antiplatelets
Pre-Book The Lipid Regulators Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Lipid Regulators Market?
Leading firms in the lipid regulator market are innovating advanced oral treatments to manage escalated low-density lipoprotein (LDL) cholesterol levels prevalent in heart disease patients. These oral lipid-lowering remedies are tailored for patients plagued with an inherited genetic irregularity triggering high cholesterol or those suffering from heart disorders. For instance, in May 2022, Sun Pharmaceutical Industries Limited, an India-based generic specialty pharmaceutical firm, introduced the oral drug Bempedoic Acid Brillo in India. This drug serves as a novel therapeutic solution for individuals with cardiac issues facing high LDL cholesterol. Its dual-action mechanism involves the inhibition of ATP citrate lyase, an enzyme critical to cholesterol production, and stimulation of AMP-activated protein kinase (AMPK) for regulating cholesterol synthesis in the liver. Bempedoic acid is administered orally once daily, offering more convenience to patients compared to some other cholesterol-lowering pharmaceuticals.
Who Are the Key Players In The Lipid Regulators Market?
Major companies operating in the lipid regulators market are:
• Pfizer Inc.
• AbbVie Inc.
• Bayer AG
• Sanofi SA
• AstraZeneca plc
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Novartis AG
• Amgen Inc.
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Hetero Drugs Limited
• Dr. Reddy's Laboratories Ltd.
• Biocon Ltd.
• Alnylam Pharmaceuticals Inc.
• Amarin Corporation plc
• Arrowhead Pharmaceuticals Inc.
• Kowa Pharmaceuticals America Inc.
• Esperion Therapeutics Inc.
• Bentley Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Limited
• Andrx Corporation
What Are The Regional Insights Into The Lipid Regulators Market?
North America was the largest region in the lipid regulators market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lipid regulators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
